{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T21:48:17Z","timestamp":1761169697428,"version":"build-2065373602"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,6]],"date-time":"2023-07-06T00:00:00Z","timestamp":1688601600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","valueinhealthjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.jval.2023.06.011","type":"journal-article","created":{"date-parts":[[2023,7,3]],"date-time":"2023-07-03T18:01:14Z","timestamp":1688407274000},"page":"1535-1542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Recognizing the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability, or Willingness?"],"prefix":"10.1016","volume":"26","author":[{"given":"Margherita","family":"Neri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Brassel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Silje","family":"Akerjord","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Apostolos","family":"Charos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina","family":"Schley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lotte","family":"Steuten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"32","key":"10.1016\/j.jval.2023.06.011_bib1","doi-asserted-by":"crossref","first-page":"5945","DOI":"10.1016\/j.vaccine.2007.04.070","article-title":"Do we fully understand the economic value of vaccines?","volume":"25","author":"Drummond","year":"2007","journal-title":"Vaccine"},{"issue":"11","key":"10.1016\/j.jval.2023.06.011_bib2","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1473-3099(08)70258-5","article-title":"Funding of drugs: do vaccines warrant a different approach?","volume":"8","author":"Beutels","year":"2008","journal-title":"Lancet Infect Dis"},{"issue":"10","key":"10.1016\/j.jval.2023.06.011_bib3","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.jval.2018.08.005","article-title":"Economic analysis of vaccination programs: an ISPOR good practices for outcomes research task force report","volume":"21","author":"Mauskopf","year":"2018","journal-title":"Value Health"},{"issue":"7","key":"10.1016\/j.jval.2023.06.011_bib5","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jval.2022.06.018","article-title":"The Value of Vaccines in Maintaining Health System Capacity in England","volume":"26","author":"Brassel","year":"2023","journal-title":"Value Health"},{"issue":"1","key":"10.1016\/j.jval.2023.06.011_bib6","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s40258-021-00683-z","article-title":"Towards a broader assessment of value in vaccines: the BRAVE way forward","volume":"20","author":"Bell","year":"2022","journal-title":"Appl Health Econ Health Policy"},{"issue":"21","key":"10.1016\/j.jval.2023.06.011_bib7","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1016\/j.vaccine.2019.04.020","article-title":"Case fatality rates of invasive meningococcal disease by serogroup and age: a systematic review and meta-analysis","volume":"37","author":"Wang","year":"2019","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jval.2023.06.011_bib8","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s40121-018-0213-2","article-title":"Systematic review of invasive meningococcal disease: sequelae and quality of life impact on patients and their caregivers","volume":"7","author":"Olbrich","year":"2018","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jval.2023.06.011_bib9","first-page":"237","article-title":"Meningococcal disease: changes in epidemiology and prevention","volume":"4","author":"Chang","year":"2012","journal-title":"Clin Epidemiol"},{"issue":"2","key":"10.1016\/j.jval.2023.06.011_bib10","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s10198-019-01129-z","article-title":"Economic evaluation of meningococcal vaccines: considerations for the future","volume":"21","author":"Christensen","year":"2020","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jval.2023.06.011_bib11","doi-asserted-by":"crossref","first-page":"261","DOI":"10.3389\/fpubh.2020.00261","article-title":"Health technology assessment for vaccines against rare, severe infections: properly accounting for serogroup B meningococcal vaccination\u2019s full social and economic benefits","volume":"8","author":"Stawasz","year":"2020","journal-title":"Front Public Health"},{"issue":"1","key":"10.1016\/j.jval.2023.06.011_bib12","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1080\/14760584.2021.1878030","article-title":"Use of cost-effectiveness analyses for decisions about vaccination programs for meningococcal disease in the United States, United Kingdom, The Netherlands, and Canada","volume":"20","author":"Huang","year":"2021","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.jval.2023.06.011_bib16","article-title":"Overview of meningococcal epidemiology and national immunization programs in children and adolescents in 8 Western European countries","volume":"10","author":"Cardoso","year":"2022","journal-title":"Front Pediatr"},{"issue":"2 suppl","key":"10.1016\/j.jval.2023.06.011_bib21","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jadohealth.2016.03.041","article-title":"Deciphering the burden of meningococcal disease: conventional and under-recognized elements","volume":"59","author":"Martin\u00f3n-Torres","year":"2016","journal-title":"J\u00a0Adolesc Health"},{"issue":"13","key":"10.1016\/j.jval.2023.06.011_bib22","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1016\/j.vaccine.2010.11.090","article-title":"Rethinking the benefits and costs of childhood vaccination: the example of the Haemophilus influenzae type b vaccine","volume":"29","author":"B\u00e4rnighausen","year":"2011","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.jval.2023.06.011_bib23","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s40258-016-0224-7","article-title":"Methodological challenges to economic evaluations of vaccines: is a common approach still possible?","volume":"14","author":"Jit","year":"2016","journal-title":"Appl Health Econ Health Policy"},{"issue":"suppl 1","key":"10.1016\/j.jval.2023.06.011_bib24","doi-asserted-by":"crossref","first-page":"A29","DOI":"10.1016\/j.vaccine.2016.12.001","article-title":"Moving beyond traditional valuation of vaccination: needs and opportunities","volume":"35","author":"Bloom","year":"2017","journal-title":"Vaccine"},{"issue":"46","key":"10.1016\/j.jval.2023.06.011_bib25","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1016\/j.vaccine.2017.09.048","article-title":"Estimating the full public health value of vaccination","volume":"35","author":"Gessner","year":"2017","journal-title":"Vaccine"},{"issue":"441","key":"10.1016\/j.jval.2023.06.011_bib26","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaj2345","article-title":"The broad socioeconomic benefits of vaccination","volume":"10","author":"Bloom","year":"2018","journal-title":"Sci Transl Med"},{"issue":"1","key":"10.1016\/j.jval.2023.06.011_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/s12916-015-0446-9","article-title":"The broader economic impact of vaccination: reviewing and appraising the strength of evidence","volume":"13","author":"Jit","year":"2015","journal-title":"BMC Med"},{"issue":"1","key":"10.1016\/j.jval.2023.06.011_bib28","first-page":"85","article-title":"Modern infectious diseases: macroeconomic impacts and policy responses","volume":"60","author":"Bloom","year":"2022","journal-title":"J\u00a0Econ Lit"},{"key":"10.1016\/j.jval.2023.06.011_bib29","doi-asserted-by":"crossref","first-page":"g5725","DOI":"10.1136\/bmj.g5725","article-title":"Re-evaluating cost effectiveness of universal meningitis vaccination (Bexsero) in England: modelling study","volume":"349","author":"Christensen","year":"2014","journal-title":"BMJ"},{"issue":"12","key":"10.1016\/j.jval.2023.06.011_bib30","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1002\/hec.3259","article-title":"Measuring health spillovers for economic evaluation: a case study in meningitis","volume":"25","author":"Al-Janabi","year":"2016","journal-title":"Health Econ"},{"issue":"5","key":"10.1016\/j.jval.2023.06.011_bib31","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.4161\/hv.23888","article-title":"Cost-effectiveness of vaccination against meningococcal B among Dutch infants: crucial impact of changes in incidence","volume":"9","author":"Pouwels","year":"2013","journal-title":"Hum Vaccin Immunother"},{"author":"Hernandez-Villafuerte","key":"10.1016\/j.jval.2023.06.011_bib32"},{"issue":"12","key":"10.1016\/j.jval.2023.06.011_bib33","doi-asserted-by":"crossref","first-page":"1692","DOI":"10.1016\/j.vaccine.2019.01.013","article-title":"The cost-of-illness for invasive meningococcal disease caused by serogroup B Neisseria meningitidis (MenB) in Germany","volume":"37","author":"Scholz","year":"2019","journal-title":"Vaccine"},{"author":"Zhang","key":"10.1016\/j.jval.2023.06.011_bib35"},{"author":"Brassel","key":"10.1016\/j.jval.2023.06.011_bib38"},{"issue":"2","key":"10.1016\/j.jval.2023.06.011_bib39","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.jval.2016.11.027","article-title":"Using cost-effectiveness analysis to address health equity concerns","volume":"20","author":"Cookson","year":"2017","journal-title":"Value Health"},{"key":"10.1016\/j.jval.2023.06.011_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.jvacx.2021.100096","article-title":"Realising the broader value of vaccines in the UK","volume":"8","author":"Brassel","year":"2021","journal-title":"Vaccin X"},{"author":"Rubis","key":"10.1016\/j.jval.2023.06.011_bib41"}],"container-title":["Value in Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030280?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1098301523030280?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T01:32:43Z","timestamp":1761096763000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1098301523030280"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S1098301523030280"],"URL":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.011","relation":{},"ISSN":["1098-3015"],"issn-type":[{"type":"print","value":"1098-3015"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Recognizing the Broader Value of Meningococcal Vaccination: A Matter of Evidence, Ability, or Willingness?","name":"articletitle","label":"Article Title"},{"value":"Value in Health","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jval.2023.06.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 International Society for Pharmacoeconomics and Outcomes Research, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}